Intelligent Bio Solutions Announces Study Results for Codeine Detection

What Happened Intelligent Bio Solutions Inc. (INBS) filed a Form 8-K on September 1, 2026 (Item 7.01) to disclose a press release announcing the results of its latest Method Comparison Study for the Intelligent Fingerprinting Drug Screening System aimed at detecting the opiate codeine. The press release is furnished as Exhibit 99.1 to the Form 8-K and the Company notes the disclosure is qualified by the full text of that release.

Key Details

• Form 8-K filed September 1, 2026 under Item 7.01 (Regulation FD Disclosure).
• Press release dated September 1, 2026 announcing results of a Method Comparison Study for detecting the opiate codeine using the Intelligent Fingerprinting Drug Screening System (Exhibit 99.1).
• Exhibit listing also included the Inline XBRL cover page (Item 9.01), but no additional financial statements or other material items were reported in this filing.
• The company states the 8-K disclosure is qualified in its entirety by the full text of the furnished press release.

Why It Matters Product validation news—like a Method Comparison Study demonstrating detection of a specific opiate—can be important for investors because it relates directly to the performance and commercial readiness of the Company’s drug screening technology. Because this information was furnished under Regulation FD, it was publicly released to ensure fair disclosure; investors should read the full press release (Exhibit 99.1) for the complete study details and any stated implications. The filing itself does not present financial results or quantify economic impact.